Melissa N.F. Nelson

Melissa N.F. Nelson

Auto-generated profile, based on publicly available information

Melissa N.F. Nelson

Department of Psychiatry, and Department of Molecular Pharmacology and Therapeutics, Columbia University, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSrijita Bhowmik
Srijita Bhowmik
JGJuraj Galeta
Juraj Galeta
VHVáclav Havel
Václav Havel
MNMelissa Nelson
Melissa Nelson
AFAbdelfattah Faouzi
Abdelfattah Faouzi
DSDalibor Sames
Dalibor Sames
Mitragynine (MG) is the most abundant alkaloid component of the psychoactive plant material “kratom”, which according to numerous anecdotal reports shows efficacy in self-medication for pain syndromes, depression, anxiety, and substance use disorders. We have developed a synthetic method for selective functionalization of the unexplored C11 position of the MG scaffold (C6 position in indole numbering) via the use of an indole-ethylene glycol adduct and subsequent iridium-catalyzed borylation. Through this work we discover that C11 represents a key locant for fine-tuning opioid receptor signaling efficacy. 7-Hydroxymitragynine (7OH), the parent compound with low efficacy on par with buprenorphine, is transformed to an even lower efficacy agonist by introducing a fluorine substituent in this position (11-F-7OH), as demonstrated in vitro at both mouse and human mu opioid receptors (mMOR/hMOR) and in vivo in mouse analgesia tests. Low efficacy opioid agonists are of high interest as candidates for generating safer opioid medications with mitigated adverse effects.

22 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSoumen Chakraborty
Soumen Chakraborty
JDJeffrey F. DiBerto
Jeffrey F. DiBerto
AFAbdelfattah Faouzi
Abdelfattah Faouzi
SBSarah M. Bernhard
Sarah M. Bernhard
AGAnna M. Gutridge
Anna M. Gutridge
SMSusruta Majumdar
Susruta Majumdar
Dried kratom leaves are anecdotally used for the treatment of pain, opioid dependence, and alcohol use disorder. We have previously shown that kratom’s natural products (mitragynine) and semi-synthetic analogs (7-hydroxy mitragynine (7OH) and mitragynine pseudoindoxyl) are mu opioid receptor (MOR) agonists that show minimal β-arrestin2 recruitment. To further investigate the structure activity relationships of G-protein potency, efficacy, and β-arrestin2 recruitment, we diversified the mitragynine/7OH templates at the C9, -10 and -12 positions of the aromatic ring of the indole moiety. Three lead C9 analogs, synthesized by swapping the 9-methoxy group with varied substituents, namely phenyl ( SC11 ), methyl ( SC12 ), 3’-furanyl ( SC13 ), were further characterized using a panel of in vitro and ex vivo electrophysiology assays. All three compounds were partial agonists with lower efficacy than both DAMGO and morphine in heterologous G-protein assays and synaptic physiology. SC11-13 also showed lower recruitment of both β-arrestin subtypes compared to DAMGO, and in assays with limited MOR receptor reserve, the G-protein efficacy of SC11, SC12 and SC13 was comparable to buprenorphine. In mouse models, at equianalgesic doses SC13 showed MOR-dependent analgesia with potency similar to morphine without respiratory depression, hyperlocomotion, constipation, or place conditioning. Taken together, these results suggest that MOR agonists with a G-protein efficacy profile similar to buprenorphine can be developed into opioids that are effective analgesics with greatly reduced liabilities.